Mar 1 |
Amneal Pharmaceuticals Non-GAAP EPS of $0.14 beats by $0.05, revenue of $617M misses by $17.86M
|
Mar 1 |
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
|
Feb 29 |
Amneal Pharmaceuticals Q4 2023 Earnings Preview
|
Feb 27 |
Amneal signs exclusive European licensing agreement with Zambon Biotech for IPX203
|
Feb 27 |
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
|
Feb 18 |
Insiders the biggest winners as Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) market cap rises to US$1.8b
|
Feb 13 |
Amneal to Participate at Upcoming Investor Conference
|
Feb 8 |
Amneal resubmits FDA application for Parkinson's disease drug
|
Feb 8 |
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
|
Jan 31 |
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
|